This year's LINNC meeting in Paris saw over 1,000 delegates from 67 countries participate in live case demonstrations, literature reviews, and therapy workshops. MicroPort NeuroTech, a liberty sponsor for the event, ran a technology booth with support from Shanghai R&D and expert user Dr. Bruno Parente. Twenty-six physicians participated in hands-on product demonstrations and training, focusing on NUMEN™, NUMEN™ Silk, NeuroHawk™, X-track™, APOLLO™, and Bridge™. Feedback was extremely positive, with encouragement for MicroPort NeuroTech to continue sharing its innovative solutions, particularly in ICAD, recognized as a major strength by the international community.

Paris, France — On June 3-5, MicroPort NeuroTech participated in the annual LINNC meeting, making a significant impact on the international community and attending physicians. LINNC Paris, led by Jacques Moret, Laurent Spelle, and Vitor Mendes Pereira, is a leading congress in interventional neuroradiology. The educational course, based on clinical cases, supports the INR community in providing the best treatments for patients.

Shanghai, China — On June 14-16, MicroPort NeuroTech showcased its cutting-edge cerebrovascular technologies at the 1st SNF-ALICE forum, drawing significant attention. Experts from around the world gathered for live cases and hands-on sessions, including a demonstration of Tubridge™ by Professors Huang Qinghai and Zhou Yu. Concurrently, the MindShare Campaign hosted Dr. Juan Carlos Miranda and Dr. Rafael Kiyuze De Freitas, who explored the company's headquarters and products. This event strengthened international ties and highlighted MicroPort NeuroTech's commitment to innovative medical solutions.

Shanghai, China - On June 20, 2024, MicroPort NeuroTech announced that its PathFinder™ carotid balloon dilation catheter has received market authorization from the National Medical Products Administration (NMPA). Designed for percutaneous transluminal angioplasty, PathFinder™ effectively dilates and unclogs narrowed carotid arteries. This new addition expands MicroPort NeuroTech’s portfolio of neurointerventional products and enhances treatment options for cerebrovascular diseases. The company now offers 20 approved products across key neurovascular therapy areas.

Brasilia, Brazil - Recently, MicroPort NeuroTech announced the first implantation of its Tubridge™ Flow Diverter in Brazil. The procedure was performed at Hospital Brasilia by Dr. Bruno Parente, with remote guidance from Prof. Jianmin Liu of Shanghai Changhai Hospital. The Tubridge™ impressed operators with its immediate flow diverting capabilities. This marks a significant milestone as Tubridge™, already seeing success in Argentina, expands its presence in global markets.

Shanghai, China - On May 14, 2024, the world’s first Percutaneous Neuroprotection for Carotid Artery Remodeling (PCAR) was successfully performed at Fudan University Affiliated Pudong Medical Center. Developed jointly by MicroPort NeuroTech and Prof. Bo Yu’s team, the PCAR system addresses severe carotid stenosis with minimal trauma through puncture rather than surgical incision. This breakthrough combines engineering with medicine, overcoming limitations of traditional TCAR procedures. The PCAR system represents a significant advancement in carotid artery stenosis treatment, offering a high-quality, less invasive option for patients.

On May 10, MicroPort NeuroTech (Shanghai) Co., Ltd., a subsidiary of MicroPort NeuroTech Limited, was named one of Shanghai's “Specialized and Sophisticated Enterprises 2024.” This prestigious recognition highlights the company's brand value, market share, innovation, and social contributions. MicroPort NeuroTech is committed to continuing its quality-led and innovation-driven development, aiming to provide high-quality, accessible solutions for cerebrovascular disease treatment.

On April 29 in Paris, the first commercial implantations of the NUMEN™ Embolization Coil by MicroPort NeuroTech were completed at Rothschild Foundation Hospital by Professor Michel Piotin and his team. The coil received high praise for its drilling ability, dense packing, and stable basket formation. Approved by the French health technology assessment agency, the NUMEN™ Coil series now have medical insurance codes, marking a significant step in making aneurysm embolization therapy more accessible. This event marks MicroPort NeuroTech's entry into its 16th international market, solidifying its global leadership in neurointerventional surgery.